Key takeaways
Otezla (apremilast) and Humira (adalimumab) are both medications used to treat plaque psoriasis and psoriatic arthritis, but they have some important differences. Otezla is a phosphodiesterase-4 (PDE-4) inhibitor taken by mouth twice daily, while Humira is a biologic disease-modifying antirheumatic drug (DMARD) injected under the skin, usually every other week. Otezla is also approved for mouth sores from Behçet’s disease, whereas Humira is used for a wider range of autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Otezla requires a gradual increase in dosage to minimize side effects like nausea and diarrhea. Generic versions of Otezla are FDA-approved but not yet available, whereas Humira has several biosimilars. Common side effects of Otezla include diarrhea and nausea, while Humira can cause injection-site reactions and increase the risk of infections. Additionally, Humira may raise the risk of lymphoma and skin cancer and cannot be used with live vaccines.
